; (2) downregulation of IFN signaling (e.g., loss of function mutation of JAK215,46); (3) suppression of presentation of neoantigens on the tumor cell surface to reduce T cell recognition [e.g., mutation/deletion or downregulation of the molecules involved in antigen processing in the endoplasmic reticulum (ER)12 (e.g., TAP etc.)or antigen surface presentation (e.g., MHC or β2-microglobulin (B2M) protein15]; (4) recruitment of immuno-suppressive cells [e.g., myeloid-derived suppressor cells (MDSCs)] or regulatory T cells directed to the tumor microenvironment47. The gene discussed is B2M; the disease is neoplasm.